Encompass Health (EHC) Stock Forecast & Price Target

Encompass Health is attractive fundamentally because it operates in a structurally undersupplied inpatient rehabilitation market where demand from an aging patient base outpaces industry capacity, supporting durable same-store and volume growth. Its 2Q results reinforced that thesis, with adjusted EBITDA-NCI beating consensus by 3% despite an $11.5 million headwind from net SDPs, same-store volume growth of 2.8% year over year, and a $15 million raise to adjusted EBITDA guidance. The company’s moat is strengthened by leading scale, high-acuity mix, strong clinical differentiation, and a flexible balance sheet with only 1.9x leverage, enabling continued bed expansion, buybacks, and cash-flow funded growth.

Encompass Health is viewed negatively because its inpatient rehabilitation model faces persistent margin pressure from higher staffing costs, turnover, and reimbursement that generally lags operating inflation. The company also faces meaningful regulatory risk, as MedPAC has repeatedly recommended a -7% cut to IRF Medicare FFS rates, which is estimated to reduce adjusted EBITDA by about -18%, while IRF stays at roughly $25k versus about $17k in acute care may invite further scrutiny. In addition, volume growth sustainability is uncertain, Medicare Advantage plans are tightening admissions and denials, and rising maintenance capex could absorb cash that would otherwise support expansion, repurchases, or dividends.